+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The treatment of cancer-associated venous thromboembolism in the era of the novel oral anticoagulants



The treatment of cancer-associated venous thromboembolism in the era of the novel oral anticoagulants



Expert Opinion on PharmacoTherapy 16(16): 2391-2394



The initial and long-term administration of low-molecular-weight heparin (LMWH) is now regarded as the treatment of choice for the therapy of patients with cancer-associated venous thromboembolism (CAT). However, LMWH requires daily subcutaneous injections and can induce thrombocytopenia. In recent years, novel direct oral anticoagulants (DOAC) have emerged to potentially replace conventional treatments. The advantages and limitations of conventional approaches for the treatment of CAT are presented and analyzed based on available findings and on recommendations from international guidelines, as is the potential for the DOAC. LMWH still remains the mainstay of initial and long-term treatment of CAT. Vitamin K antagonists may have a role in patients with inactive cancer and in those with severe renal failure. Whether there is a potential for the DOAC is uncertain. Indeed, most patients with advanced cancer were excluded from the trials addressing their value. Although available findings are encouraging, before implementing them in the routine clinical practice there is the need for dedicated studies in which cancer patients, whichever their severity and prognosis, are allocated to either DOAC or LMWH, which represent the standard of treatment for patients with CAT.

(PDF emailed within 0-6 h: $19.90)

Accession: 059113567

Download citation: RISBibTeXText

PMID: 26360919

DOI: 10.1517/14656566.2015.1088003


Related references

Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. Hamostaseologie 37(4): 241-255, 2017

Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants. Annals of Oncology 2019, 2019

Direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism. Blood Research 49(2): 77-79, 2014

Direct oral anticoagulants: now also for prevention and treatment of cancer-associated venous thromboembolism?. Hematology. American Society of Hematology. Education Program 2017(1): 136-143, 2018

Direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer. Medicina Clinica 2019, 2019

Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer. Internal and Emergency Medicine 10(6): 651-656, 2017

The use of direct oral anticoagulants in the treatment of acute venous thromboembolism in cancer patients. Expert Review of Hematology 11(6): 487-494, 2018

Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis 16(9): 1891-1894, 2018

Hypoalbuminemia for the prediction of venous thromboembolism and treatment of direct oral anticoagulants in metastatic gastric cancer patients. Gastric Cancer 2019, 2019

Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants. Journal of Oncology Pharmacy Practice 2017: 1078155217730129, 2017

Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials. Drugs 2019, 2019

Direct oral anticoagulants for the treatment of acute venous thromboembolism in patients with cancer: a meta-analysis of randomised controlled trials. European Respiratory Journal 50(3), 2017

OC-13 - Safe and effective use of direct oral anticoagulants (DOAC) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism. Thrombosis Research 140 Suppl 1: S173-S174, 2016

International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet. Oncology 17(10): E452-E466, 2016

New oral anticoagulants for the treatment ofA venous thromboembolism. 2013